COVID-19: Antitrust Considerations for Competitor Collaborations

On March 23, 2020, Cravath prepared for its clients a resource entitled “COVID‑19: Antitrust Considerations for Competitor Collaborations,” which examines antitrust concerns that may be considered by the U.S. Department of Justice or U.S. Federal Trade Commission if competitor companies cooperate in endeavors related to the pandemic. Such endeavors may include benchmarking best practices for safe distribution of products, joint production of medical equipment and supplies, and joint research and development initiatives for a vaccine or antivirals. The materials lay out what types of collaborations are considered immune from antitrust scrutiny and which are unlawful, and includes “dos and don’ts” of collaboration along with examples of laws that may form the basis for an antitrust defense.

Please click here to read the resource.